A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT02340234. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of lebrikizumab administered subcutaneously (SC) in adult participants with persistent moderate to severe atopic dermatitis (AD) who are inadequately controlled by topical corticosteroids (TCS). The study includes a screening visit, a 2-week run-in period, a 12-week blinded treatment period, and an 8-week safety follow-up period. Following screening visit, eligible participants will enter in run-in period (Days - 14 to - 1) during which a protocol-specified topical therapy regimen will be initiated. At the end of the run-in period, participants who have: 1) demonstrated compliance with the protocol-specified TCS regimen, and 2) who continue to fulfill the eligibility criteria will be randomized.
Study identification
- NCT ID
- NCT02340234
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 212 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2015 (Type not available)
- Primary completion
- Apr 2016 (Actual)
- Completion
- Apr 2016 (Actual)
- Last update posted
- Oct 2, 2017
2015 – 2016
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dermatology Research Associate | Los Angeles | California | 90045 | — |
| UCSD Division of Dermatology | San Diego | California | 92122 | — |
| Univ of Calif-San Francisco | San Francisco | California | 94115 | — |
| University of Colorado; Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| Ameriderm Research | Ormond Beach | Florida | 32174 | — |
| Olympian Clinical Research | Tampa | Florida | 33609 | — |
| Northwestern University Feinberg School Of Medicine | Chicago | Illinois | 60611 | — |
| University of Iowa Healthcare; Dermatology | Iowa City | Iowa | 52242 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Somerset Skin Centre | Troy | Michigan | 48084 | — |
| Washington University; Dermatology | St Louis | Missouri | 63110 | — |
| Sadick Research Group | New York | New York | 10075 | — |
| Oregon Health & Science University; Department of Dermatology | Portland | Oregon | 97239-4501 | — |
| University of Texas Medical School-Houston | Houston | Texas | 77030 | — |
| Dermatology Clinical Research Center of San Antonio | San Antonio | Texas | 78229 | — |
| Virginia Clinical Research Inc. | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02340234, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2017 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02340234 live on ClinicalTrials.gov.